Should-Read: Ben Thompson:The GDPR and Facebook and Google, Intelligent Tracking Prevention, Data Portability and Social Graphs

Should-Read: We seem to be headed toward a future in which governments—at least in Europe—both entrench and then heavily regulate Google and Facebook, with their information edge creating the possibility that they will be for the 21st century very much what AT&T in the United States was for the bulk of the 20th century:

Ben Thompson: THE GDPR AND FACEBOOK AND GOOGLE, INTELLIGENT TRACKING PREVENTION, DATA PORTABILITY AND SOCIAL GRAPHS: “Several folks have suggested that the GDPR’s requirements around data portability… https://stratechery.com/2017/the-gdpr-and-facebook-and-google-intelligent-tracking-prevention-data-portability-and-social-graphs/

…including that it be machine accessible (i.e. not just a PDF) will help new networks form, but in fact the opposite is the case…. It’s a reasonable regulation: my friend on Facebook didn’t give permission for their information to be given to Snapchat, for example. It does, though, make it that much more difficult to bootstrap a Facebook competitor…

Should-Read: Jeff Stein: GOP senators are rushing to pass Graham-Cassidy. We asked 9 to explain what it does

  • Should-Read: Republican Senators can find nobody who will, even in public (with private reservations), even pretend to agree with them that GC will not result in massive losses of health insurance coverage by tens of millions. Not even Avik Roy. Nobody. Literally nobody:

Jeff Stein: GOP senators are rushing to pass Graham-Cassidy. We asked 9 to explain what it does: “Republican senators are struggling to articulate why they are rushing to pass their last-ditch effort to repeal and replace Obamacare… https://www.vox.com/policy-and-politics/2017/9/20/16333876/republican-senators-graham-cassidy

The GOP senators insisted that the tens of billions in cuts to federal health spending proposed in the bill would not result in coverage losses because, they said, the states would have more flexibility. “They can do it with less money,” said Sen. Jim Inhofe (R-OK), who was unable to explain how or why…

New federal antitrust legislation recognizes U.S. workers are not only consumers

Sen. Amy Klobuchar of Minnesota on Capitol Hill in Washington, D.C.

The introduction of two new antitrust bills by Sen. Amy Klobuchar, D-MN, last week indicates that Democrats are serious about making antitrust enforcement a central plank in their economic policy platform. In July, congressional Democrats released “A Better Deal,” intended to be the jumping off point for their policy agenda for the 2018 elections, and antitrust was a major plank. Sen. Klobuchar’s bills would implement many of the antitrust policy issues highlighted in “A Better Deal.”

The increased interest in issues of competition and antitrust enforcement on the policy side is matched by that on the research side. As examples of market concentration mount, researchers are increasingly asking whether any number of the economic ills we’re experiencing—from the rise in inequality to decreased business investment, stagnant wages for less-educated workers, and the decline in startups—are perhaps all related to one underlying cause: the growth in market power of a small handful of “superstar” firms in their fields.

Equitable Growth has done a lot of work on the subject of competition and antitrust recently, including analyses of some of the most recent research on the subject, as well as a case study of the telecommunications industry and data analysis of merger enforcement actions. A critical question is what the relationship is between companies’ market power and inequality. There seem to be multiple channels through which greater market power and lower competition could increase economic inequality. While antitrust issues have generally been viewed from a consumer perspective over the past 30 years, focusing on the consumer price effects of mergers, this emphasis on whether sellers create monopolies for their products ignores that buyers can also create a monopsonic market for the prices they pay.

A monopsonic market is one in which a buyer of a good or service has the power to pay lower prices than he or she would have to in a competitive market. In the case of a labor market, monopsony refers to a firm or firms’ ability to restrict wages below what they would be in a competitive market. If an increasingly smaller handful of firms are dominating their industries, then they have fewer competing buyers for labor. The classic and most extreme example of this phenomenon is the “company town,” in which there is only one employer and therefore workers are easily exploited. Of course, that rarely happens today—though companies do have varying degrees of monopsonic power.

The Clayton Act of 1914—one of the foundational antitrust laws in the United States—bans mergers that would create a monopoly, but there is no explicit reference to monopsony. Sen. Klobuchar’s Consolidation Prevention and Competition Promotion Act of 2017 proposes to make explicit that monopsony should be treated the same way. By incorporating monopsony into Clayton’s legislative language, mergers that allow a company to unfairly lower the prices it pays its employees or suppliers would not be allowed.

The explicit incorporation of monopsony into an existing statute is an example of one of the central tensions in the debate among think tank scholars, policymakers, and federal antitrust enforcers. The question is whether policymakers already have the proper antitrust tools they need and just need to enforce them more strenuously, or whether new companies and business models in the 21st century economy demand new tools. Sen. Klobuchar’s bills seem to take a “both/and” approach, calling for greater resources for our existing enforcement agencies, as well as the creation of new antitrust tools. These tools include the explicit incorporation of “monopsony” into the Clayton Act’s text, as well as the creation of a new Office of the Competition Advocate along the lines of the Consumer Financial Protection Bureau.

More work is needed to understand how either updated or new antitrust policies could be implemented and might play out in the economy. That’s why Equitable Growth is proud to announce that we’re partnering with American University’s Washington College of Law to host an event on October 27, 2017, in Washington, D.C. “Unlocking the Promise of Antitrust Enforcement” will feature presentations by leading scholars in antitrust law and economics, along with discussion by prominent antitrust practitioners to explore whether there is scope for more vigorous enforcement of existing law. You can can register to attend and learn more here.

Should-See: Janet Napolitano et al.: The Future of NAFTA and the State of U.S. Mexico Relations

Should-See: UC President Janet Napolitano is organizing a NAFTA conference in DC this week:

Janet Napolitano et al.: The Future of NAFTA and the State of U.S. Mexico Relations: “September 21 :: U.C. Washington Center :: 1608 Rhode Island Ave NW… <http://delong.typepad.com/uc_nafta_program_f11.pdf” title=”uc_nafta_program_F1[1].pdf>

…Peter Cowhey… Thomas d’Aquino… Michael Froman… Arturo Sarukhan… Will Marshall… Luis de la Calle… Ari Giovenco—Director… Antonio Rodriguez-Lopez… Luis Serra… Carlos Elizondo… Janet Napolitano… Alejandro Poiré… Ron Brownstein… Gerardo Esquivel… Harley… Chris Smith… Mark Warner… Gustavo Merino… David Aguilar… Rafael Fernández de Castro… Diana Villiers Negroponte… Antonio Ortiz-Mena… Kevin de León… Maria Echaveste… Gerónimo Gutiérrez…

Should-Read: CPPC: California Assembly Passes Bill to Make Drug Prices Transparent

Should-Read: Everybody outside California should be paying attention to see if its policies do in fact work:

CPPC: California Assembly Passes Bill to Make Drug Prices Transparent: “The California Assembly passed Senate Bill 17… prescription drug price transparency… 66-9… https://www.thecppc.com/single-post/2017/09/13/California-Assembly-Passes-Bill-to-Make-Drug-Prices-Transparent

…The chief sponsor, State Senator Ed Hernandez, praised the outcome and said “drug companies threw everything they had at this bill, but the Assembly stood up for consumers.”… SB 17 requires drug companies to notify health insurance companies and government health plans such as Medi-Cal of certain drug price increases… at least 60 days before the price hikes… [of] any increase that exceeds 16% over a two-year period. The companies… have to provide justifications…. Drug companies fought against this bill every step of the way, taking out newspaper ads, sending many different lobbyists to Sacramento, and claiming that the bill would be ineffective.

While SB 17 will not solve the problem of high drug prices on its own, it is a good beginning. The prescription drug market is plagued by a lack of good information about prices and the reasons for their increase. Supreme Court Justice Louis Brandeis wrote that sunlight is the best disinfectant, and transparency will promote lower drug prices and set the stage for further reforms…

Should-Read: Josh Bivens: An evidence-based Fed would hold rates steady in September

Should-Read: Josh Bivens sounds a little… shrill this morning. I see the world much as he does. The longer I watch this, the more I think that the problems lie deep in Fed governance—specifically, in the failure of the Board of Governors and of Congress supervising the Board to insist that the “corporatist” structure of regional bank boards of directors be honored in reality by appointing people who genuinely know and will argue for policies that consider the interests of different economic groups. The Federal Reserve Act says that the one-third who are class “A” directors will:

represent stockholding banks…

and that the two-thirds who are class “B” and “C” directors will be:

chosen with due but not exclusive consideration to the interests of agriculture, commerce, industry, services, labor and consumers…

But when has this ever been honored in substance?

Josh Bivens: An evidence-based Fed would hold rates steady in September: “The Federal Open Market Committee (FOMC) meets today and tomorrow to determine whether or not to raise interest rates… http://www.epi.org/blog/an-evidence-based-fed-would-hold-rates-steady-in-september/

…The FOMC has raised rates three times since December 2016. The evidence arguing that these increases were wise or necessary was thin at best. That rationale for raising interest rates is to rein economic growth that threatens to drive down unemployment so low that workers will be empowered to achieve unsustainably large wage increases. The worry is that such wage increases could push price inflation over the Fed’s target rate. But the real-world data that exists on every link of this causal chain shows that such worries are baseless….

The rate increase that happened in June was particularly dispiriting for those hoping the Fed would continue to follow the evidence-based approach…. The economic data… gave plenty of reasons why a data-dependent Fed might worry that it was riskier to raise rates… than to stand pat for a couple of months. Yet the Fed raised rates. Data since June has been much softer. The Fed’s preferred inflation measure has decelerated significantly, and any upward creep of wage growth has stopped. There just is no case for continuing to raise rates in the face of this data.

While the outcome of any single FOMC meeting is not crucial for the American middle class, what this week’s meeting signals for the commitment of the Fed to genuine full employment is crucial…

Must- and Should-Reads: September 19, 2017


Interesting Reads:

Should-Read: Ann Marie Marciarille: Patent Transfer to Trigger Sovereign Immunity Defense

Should-Read: Ann Marie Marciarille: Patent Transfer to Trigger Sovereign Immunity Defense: “It is absolutely fascinating to  read that that Allergan and the St. Regis Mohawk Tribe have reportedly made arrangements for transfer of certain patent rights… http://www.marciarille.com/2017/09/patent-transfer-to-trigger-state-action-immunity-defense.html

…in exchange for a substantial fee, to a sovereign, such as a Native American tribe, that may invoke sovereign immunity to defeat patent challenge litigation. The hot new dry eye drug Restasis would then be licensed back to Allergan by the tribe.

The article in the New York Times described this approach as “novel” and made me curious about other such transfers of intellectual property rights to defeat patent challenges in this way.  I can’t find any others. It takes a kind of genius to think of such a method of gaming the legal system but no one seems to want to take credit, publicly at least. My favorite part of the narrative is the one that says the St. Regis Mohawk Tribe proposed the arrangement after being schooled in it by an apparently free floating law firm.  Right…

Must-Read: George Akerlof (1979): The Case against Conservative Macroeconomics: An Inaugural Lecture

Must-Read: George Akerlof was right forty years ago to say that the “microfoundations” of Lucas and Sargent were simply fake:

Unemployment arising because workers can’t tell what their wages really are because they are unable to observe the prices they pay, and thus confuse a downward nominal shock to incomes and prices with a downward real shock to their wages? The insistence that because most unemployment spells are short the bulk of unemployment that is medium- or long-spell is simply not there?

George Akerlof (1979): The Case against Conservative Macroeconomics: An Inaugural Lecture: “The old classical economics bases its case against the efficacy of fiscal policy on the low interest elasticity of money demand… http://delong.typepad.com/2553741.pdf

…the New Classical Economics argues that no anticipated government policy… can affect real output… not from any special assumptions concerning money demand, but… from…

  • first, that aggregate supply depends only on unanticipated price changes;
  • second, that expectations are formed rationally; and
  • third, that prices and wages adjust to clear product and labour markets….

Long durations [of unemployment] question the New Conservative view that unemployment can be blamed on aberrations of supply owing to misinformation regarding real wages. They are consistent, however, with the standard Keynesian interpretation… in which jobs are rationed…. Job rationing is… consistent with utility maximization… [by] agents… undesirous or fearful of disobeying standard business practice or of supporting such disobedience.

Must-Read: Avik Roy: Take Two: Inside Bill Cassidy’s Plan To Replace Obamacare

Must-Read: There are, as is always the case these days, a lot of misrepresentations and evasions in Avik Roy’s latest on health care “reform”.

But there is one nugget of important truth. Here it is:

Avik Roy: Take Two: Inside Bill Cassidy’s Plan To Replace Obamacare: “Because Graham-Cassidy repeals Obamacare’s individual mandate, and the Congressional Budget Office views the individual mandate as driving the majority of Obamacare’s coverage expansion, the CBO is likely to view Graham-Cassidy the same way it has viewed other GOP bills…” https://www.forbes.com/sites/theapothecary/2017/09/17/take-two-inside-bill-cassidys-plan-to-replace-obamacare/#5703ca351181

That means that when the CBO’s assessment of GC is completed, it will show something like:

  • 22 million on net losing insurance for the first public draft of BCRA;
  • 19 million on net losing insurance for the February draft of the AHCA;
  • 24 million on net losing insurance for the March draft of the AHCA; and
  • 23 million on net losing insurance for the House-passed version of the AHCA.

Even Avik Roy says so. And when even he is making an admission against interest rather than evading and obfuscating, you can take it to the bank.